Insulin lispro/pramlintide - Adocia

Drug Profile

Insulin lispro/pramlintide - Adocia

Alternative Names: BC Lis Pram; BioChaperone Lispro Pramlintide; BioChaperone® Insulin Pramlintide

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Macromolecular substances; Pancreatic hormones; Proteins
  • Mechanism of Action Islet amyloid polypeptide stimulants; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 11 Oct 2017 Adocia plans a clinical trial for Type-1 diabetes mellitus in the first half of 2018
  • 05 Jan 2017 Preclinical trials in Type-1 diabetes mellitus in France (SC)
  • 05 Jan 2017 Adocia plans clinical trial for Type-1 diabetes mellitus in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top